Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade

Cardiology

Volumn 89, Issue SUPPL. 1, 1998, Pages 10-15

  Noll, Georg ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Blood pressure; Heart rate; Hemodynamics; L type calcium channel; Mibefradil; T type calcium channel; Vascular relaxation

Indexed keywords

BENZOTHIAZEPINE DERIVATIVE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; MIBEFRADIL; NITRIC OXIDE; PHENYLALKYLAMINE; VERAPAMIL;

ANGINA PECTORIS; ANKLE EDEMA; CELL CULTURE; CELL PROLIFERATION; CONFERENCE PAPER; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FLUSHING; HEADACHE; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HYPERTENSION; INOTROPISM; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SYMPATHETIC TONE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; BENZIMIDAZOLES; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DILTIAZEM; ELECTROCARDIOGRAPHY; HEMODYNAMIC PROCESSES; HUMANS; MIBEFRADIL; TETRAHYDRONAPHTHALENES; VERAPAMIL;

EID: 2642642140     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047274     Document Type: Conference Paper

References (50)

1. Nayler WG: Second generation of calcium antagonists. Berlin, Springer, 1991, chap 1, pp 1-8.
2. Opie LH, Bühler FR, Fleckenstein A, Hansson L, Harrison DC, Poole-Wilson PA, Schwartz A, Vanhoutte PM, Braunwald E, Nayler WG, et al: International Society and Federation of Cardiology: Working Group on Classification of Calcium Antagonists for Cardiovascular Disease. Am J Cardiol 1987;60:630-632.
3. Panza JA, Epstein SE, Quyyumi AA: Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 1991;325:986-990.
4. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-2806.
5. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, De Mets DL: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335:1107-1114.
6. Braunwald E: Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982; 307:1618-1627.
7. Dougherty AH, Jackman WM, Naccarelli GV, Friday KJ, Dias VC: Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group. Am J Cardiol 1992;70:587-592.
8. Danish Verapamil Infarction Trial II - DAVIT II: Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990;66:779-786.
9. Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988;319: 385-392.
10. Held PH, Yusuf S, Furberg CD: Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. Br Med J 1989; 299:1187-1192.
11. Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, Pearle DL, Turi ZG, Schneider JF, Serfas DH, et al: Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind, placebo-controlled comparison. Circulation 1984;69:740-747.
12. Wilcox RG, Hampton JR, Banks DC, Birkhead JS, Brooksby IA, Burns-Cox CJ, Hayes MJ, Joy MD, Malcolm AD, Mather HG, et al: Trial of early nifedipine in acute myocardial infarction: The Trent study. Br Med J 1986;293:1204-1208.
13. Opie LH: Calcium channel antagonists. IV. Side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther 1988;2:177-189.
14. Küng CF, Tschudi MR, Noll G, Clozel JP, Lüscher TF: Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries. J Cardiovasc Pharmacol 1995;26:312-318.
15. Tschudi MR, Mesaros S, Lüscher TF, Malinski T: Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996;27:32-35.
16. Tschudi MR, Lüscher TF: Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 1995;91:2415-2422.
17. Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD: Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987;41:26-30.
18. Kiowski W, Erne P, Bertel O, Bolli P, Bühler F: Acute and chronic sympathetic reflex activation and anthihypertensive response to nifedipine. J Am Col Cardiol 1986;7:344-348.
19. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, ed 2. New York, Raven, 1995, pp 2815-2825.
20. Noll G, Wenzel RR, Allegranza G, Lüscher TF: Nifedipine activates sympathetic nervous system: Additive effects of cold pressor test (abstract). Eur Heart J 1994;15(suppl):190.
21. Kailasam MT, Farmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy BP, Adegbile IA, O'Connor DT: Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26: 143-149.
22. Wenzel RR, Allegranza G, Binggeli C, Lüscher TF, Noll G: Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: Role of pharmacokinetics. J Am Coll Cardiol 1997;29:1607-1614.
23. Man in't Veld AJ: Calcium antagonists in hypertension. Am J Med 1989;86:6-14.
24. Reid JL, Meredith PA, Donnelly R, Elliott HL: Pharmacokinetics of calcium antagonists. J Cardiovasc Pharmacol 1988;12:S22-S26.
25. Moreau P, Takase H, Kling CF, Shaw S, Lüscher TF: Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension 1997;29: 763-769.
26. Clozel J-P: Pharmacology of the new calcium antagonist mibefradil. J Cardiovasc Pharmacol 1996;27(suppl A):S17-S21.
27. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-759.
28. 2+ channel in cardiac tissue. Eur J Pharmacol 1995;280: 155-158.
29. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148.
30. Akaike N, Kanaide H, Kuga T, Nakamura M, Sadoshima J, Tomoike H: Low-voltage-activated calcium current in rat aorta smooth muscle cells in primary culture. J Physiol 1989;416: 141-160.
31. Hagiwara N, Irisawa H, Kameyama M: Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol 1988;395:233-253.
32. Küng CF, Tschudi MR, Noll G, Clozel JP, Lüscher TF: Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries. J Cardiovasc Pharmacol 1995;26:312-318.
33. 2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries. Naunyn Schmiedebergs Arch Pharmacol 1993;348:191-196.
34. 2+ antagonist RO 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol 1994;23:869-876.
35. Lüscher TF, Vanhoutte PM: The Endothelium: Modulator of Cardiovascular Function. Boca Raton, CRC Press, 1990, pp 1-215.
36. Lüscher TF, Noll G: The endothelium in coronary vascular control; in Braunwald E (ed): Heart Disease. Philadelphia, Saunders, 1995, pp 1-10.
37. Schmitt R, Clozel JP, Iberg N, Bühler FR: Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vase Biol 1995;15:1161-1165.
38. 3H] desmethoxyverapamil receptor, is devoid of the negative motropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4: 731-736.
39. Ezzaher A, el Houda Bouanani N, Su JB, Hitlinger L, Crozatier B: Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther 1991;257:466-471.
40. Veniant M, Clozel JP, Hess P, Wolfgang R: Ro 40-5967, in contrast to diltiazcm, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991;17:277-284.
41. Clozel JP, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713-721.
42. Orito K, Satoh K, Taira N: Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol 1993;22:293-299.
43. Guth BD: Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967). Cardiovasc Drugs Ther 1992;6:167-171.
44. Billman GE: Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation. Eur J Pharmacol 1992;229:179-187.
45. Veniant M, Clozel JP, Heudes D, Banken L, Menard J: Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats. J Cardiovasc Pharmacol 1993;21:544-551.
46. Hefti F, Clozel JP, Osterrieder W: Anthypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4- tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil. Arzneimittelforschung 1990;40:417-421.
47. Reid JL, Petrie JR, Glen SK, Meredith PA, Elliott HL: Clinical pharmacology of the novel calcium antagonist mibefradil. J Cardiovasc Pharmacol 1996;27:(suppl A):S22-S26.
48. Welker HA, Eggers H, Kleinbloesem CH: Ro 405967: Pharmacokinetics of a new calcium antagonist (abstract). Eur J Clin Pharmacol 1989;36:A304.
49. Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez AJ, Welker HA, et al: Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52: 314-323.
50. Petrie JR, Glen SK, MacMahon M, et al: Hemodynamics of mibefradil (Ro 405967), a novel calcium antagonist. J Hypertens 1995;13: 1842-1846.